Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Abiraterone (Zytiga) for Prostate Cancer Resubmission
(Pending Submission as of June 26, 2019)

Lenalidomide (Revlimid) in combination with Bortezomib and Dexamethasone for Multiple Myeloma
(Final Recommendation Issued as of June 19, 2019)

Daratumumab (Darzalex) for Multiple Myeloma
(Pending Submission as of June 18, 2019)

Pembrolizumab (Keytruda) for Non-Squamous Non-Small Cell Lung Cancer
(Notification to Implement Issued as of June 17, 2019)

Dacomitinib (Vizimpro) for Non-Small Cell Lung Cancer
(Notification to Implement Issued as of June 17, 2019)

Venetoclax (Venclexta) in combo Rituximab for Chronic Lymphocytic Leukemia
(Notification to Implement Issued as of June 17, 2019)

Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma
(Pending Submission as of June 10, 2019)

Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer
(Pending Submission as of June 3, 2019)

Find a Drug Review